The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

Then in 1890, Emil von Behring made the remarkable discovery serum derived from the blood of horses injected with diphtheria toxin contains an “antitoxin” that can be used to protect against as well ...

We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...